Surgical and medical treatment outcomes vary by PASC severity; higher severity is associated with lower rates of complete clinical success despite similar biochemical remission rates.
Emerging hormonal biomarkers (e.g., metanephrine, androstenedione) and imaging modalities (68Ga-pentixafor PET/CT) show promise in enhancing AVS accuracy and subtype diagnosis.
Integration of PASC with AVS results may guide individualized diagnostic and therapeutic strategies, optimizing patient outcomes in PA.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.